Wolverine Trading, LLC Vertex Pharmaceuticals Inc Put Options Transaction History

Wolverine Trading, LLC

$94.2 Billion
Q2 2024

Put Options

27 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $11.3 Million - $14 Million	-28,800 Reduced 44.04%	36,600 $17.2 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $2.2 Million - $2.41 Million	-5,400 Reduced 7.63%	65,400 $27.3 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $11 Million - $13.2 Million	32,200 Added 83.42%	70,800 $28.8 Million
Q3 2023 Nov 15, 2023	BUY	$338.18 - $362.46 $8.96 Million - $9.61 Million	26,500 Added 219.01%	38,600 $13.4 Million
Q2 2023 Aug 23, 2023	BUY	$314.42 - $351.91 $534,514 - $598,247	1,700 Added 16.35%	12,100 $4.26 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $2.29 Million - $2.62 Million	-8,100 Reduced 43.78%	10,400 $3.25 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $2.4 Million - $2.7 Million	8,400 Added 83.17%	18,500 $5.34 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $2.57 Million - $2.87 Million	-9,400 Reduced 48.21%	10,100 $2.96 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $1.83 Million - $2.28 Million	-7,800 Reduced 28.57%	19,500 $5.47 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $110,710 - $130,485	500 Added 1.87%	27,300 $7 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $778,844 - $983,180	-4,400 Reduced 14.1%	26,800 $5.96 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $2.07 Million - $2.31 Million	-11,400 Reduced 26.76%	31,200 $5.69 Million
Q2 2021 Aug 06, 2021	BUY	$187.49 - $221.1 $3.56 Million - $4.2 Million	19,000 Added 80.51%	42,600 $8.38 Million
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $4.29 Million - $5 Million	-20,700 Reduced 46.73%	23,600 $5.03 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $1.06 Million - $1.41 Million	5,100 Added 13.01%	44,300 $10.3 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $2.61 Million - $3.09 Million	-10,200 Reduced 20.65%	39,200 $10.6 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $2.77 Million - $3.64 Million	-12,300 Reduced 19.94%	49,400 $14.1 Million
Q1 2020 May 11, 2020	BUY	$199.77 - $247.81 $1.48 Million - $1.83 Million	7,400 Added 13.63%	61,700 $14.3 Million
Q4 2019 Feb 12, 2020	BUY	$166.71 - $223.91 $2.37 Million - $3.18 Million	14,200 Added 35.41%	54,300 $11.9 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $1.11 Million - $1.25 Million	-6,700 Reduced 14.32%	40,100 $6.69 Million
Q2 2019 Aug 20, 2019	SELL	$164.61 - $190.37 $1.14 Million - $1.31 Million	-6,900 Reduced 12.85%	46,800 $8.58 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $1.28 Million - $1.52 Million	-7,800 Reduced 12.68%	53,700 $9.88 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $4.62 Million - $5.84 Million	30,400 Added 97.75%	61,500 $9.93 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $3.87 Million - $4.45 Million	23,100 Added 288.75%	31,100 $5.99 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $636,720 - $743,946	-4,200 Reduced 34.43%	8,000 $1.3 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $2.29 Million - $2.6 Million	-16,700 Reduced 57.79%	12,200 $1.83 Million
Q3 2017 Nov 15, 2017	BUY	$148.13 - $162.24 $4.28 Million - $4.69 Million	28,900	28,900 $4.39 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

Capital World Investors Los Angeles, CA

26.7M
Shares

$13.4 Billion
2.1% of portfolio
Vanguard Group Inc Valley Forge, PA

23M
Shares

$11.5 Billion
0.21% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$10.7 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.7M
Shares

$5.89 Billion
0.24% of portfolio
Capital Research Global Investors Los Angeles, CA

8.54M
Shares

$4.29 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account